Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of chronic oral ivabradine MR vs IR in stable coronary artery disease
2012-001668-31Phase 3Completed
- Sponsor
- Servier
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivabradine in coronary arteriosclerosis (2 arms), sponsored by Servier. Primary endpoint: Occurrence of emergent adverse events over 6 months. Started Aug 2012; status: completed.
02
Drugs
ivabradine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2012-001668-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001668-31.